Mycobacterium tuberculosis in solid organ transplant donors and recipients.
Curr Opin Organ Transplant
; 26(4): 432-439, 2021 08 01.
Article
em En
| MEDLINE
| ID: mdl-34074939
ABSTRACT
PURPOSE OF REVIEW Due to impaired immune response, solid organ transplant (SOT) recipients are susceptible to tuberculosis (TB) and its subsequent morbidity and mortality. Current prevention strategies, diagnostic and treatment approach to TB infection in donors and recipients were reviewed in this article. RECENT FINDINGS:
Screening of latent tuberculosis infection (LTBI) in donors and recipients is the cornerstone of TB-preventive strategy in recipients and requires an assessment of TB risk factors, TB-specific immunity testing, and radiographic evaluation. Interferon-gamma release assay has superseded the tuberculin skin test in LTBI evaluation despite its recognized limitations. LTBI treatment should be offered to transplant candidates and living donors before transplantation and donation, respectively. Diagnosis of TB disease can be challenging because of nonspecific clinical presentation in the recipient and is limited by the sensitivity of current diagnostics. The approach to LTBI and TB disease treatment is similar to the general population, but can be challenging because of potential drug interactions and toxicities.SUMMARY:
The appropriate evaluation of donors and recipients for TB can mitigate posttransplant TB disease. Current approaches to diagnosis and treatment parallels that of immunocompetent hosts. Future research evaluating existing and novel diagnostics and treatment in transplant recipients is needed.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Transplante de Órgãos
/
Tuberculose Latente
/
Mycobacterium tuberculosis
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article